Recombinant Human PRLR Protein, Active
Beta LifeScience
SKU/CAT #: BLK-01485P-100UG

Human PRLR on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.
Recombinant Human PRLR Protein, Active
Beta LifeScience
SKU/CAT #: BLK-01485P-100UG
Collections: High-quality recombinant proteins, Other recombinant proteins
Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.
Product Overview
Description | Recombinant Human PRLR Protein is expressed from HEK293 with His tag at the C-Terminus.It contains Gln25-Asp234. |
Purity | > 95% as determined by Tris-Bis PAGE;> 95% as determined by HPLC |
Accession | P16471 |
Target Symbol | PRLR |
Synonyms | PRL-R; HPRL; MFAB; Prolactin R |
Species | Human |
Expression System | HEK293 |
Tag | C-His |
Expression Range | Gln25-Asp234 |
Mol. Weight | The protein has a predicted MW of 25.5 kDa. Due to glycosylation, the protein migrates to 35-40 kDa based on Tris-Bis PAGE result. |
Form | Lyophilized |
Formulation | Lyophilized from 0.22um filtered solution in 50mM Tris, 150nM Nacl (pH 7.5). Normally 8% trehalose is added as protectant before lyophilization. |
Endotoxin | Less than 1EU per ug by the LAL method. |
Activity | Immobilized Human PRLR, His Tag at 2ug/ml (100ul/Well) on the plate. Dose response curve for Anti-PRLR Antibody, hFc Tag with the EC50 of 12.3ng/ml determined by ELISA (QC Test). The affinity constant of 0.96nM as determined in SPR assay (Biacore T200). Contact us for detailed testing images. |
Storage | Reconstituted protein stable at -80°C for 12 months, 4°C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles. |
Shipping | Shipped at ambient temperature. |
Gene Background | Prolactin receptor (PRLR) is highly expressed in a subset of human breast cancer and prostate cancer, which makes it a potential target for cancer treatment. In clinical trials, the blockade of PRLR was shown to be safe but with poor efficacy. It is therefore urgent to develop new therapies against PRLR target. Bispecific antibodies (BsAbs) could guide immune cells toward tumor cells, and produced remarkable effects in some cancers. |